yne Therapeutics, Zeleciment Basivarsen, Z-Basivarsen, DYNE-101, Myotonic Dystrophy Type 1, DM1, ACHIEVE Trial, HARMONIA, Phase 1/2, Phase 3, Antisense Oligonucleotide

WALTHAM, Mass. — September 29, 2026 Dyne Therapeutics reported additional one-year clinical data from the multiple ascending dose (MAD)...